Status:
COMPLETED
Multi-Center Study of New Medications to Treat Vaginal Infections
Lead Sponsor:
Curatek Pharmaceuticals, LLC
Conditions:
Vaginal Infection
Eligibility:
FEMALE
12+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections
Eligibility Criteria
Inclusion
- A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:
- Capable of providing written informed consent or assent
- Currently not menstruating and not anticipating menses during treatment
- If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control
- Negative pregnancy test
- Other criteria as identified in the protocol
Exclusion
- Other infectious causes of vulvovaginitis
- Subject has recently used, or is expected to require the concomitant use of prohibited medications/products
- Nursing mother
- Use of any investigational drug within 30 days of enrollment
- History of hypersensitivity to any ingredient/component of the formulations
- Other criteria as identified in the protocol
Key Trial Info
Start Date :
June 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2018
Estimated Enrollment :
475 Patients enrolled
Trial Details
Trial ID
NCT02308007
Start Date
June 1 2015
End Date
June 1 2018
Last Update
August 4 2020
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Clinical Therapeutics
Birmingham, Alabama, United States, 35205
2
University of Alabama
Birmingham, Alabama, United States, 35294
3
Precision Trials, AZ
Phoenix, Arizona, United States, 85032
4
MomDoc Womens Health Research
Scottsdale, Arizona, United States, 85251